Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Brainsway, boosting the price target to $18.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ram Selvaraju has given his Buy rating due to a combination of factors, including Brainsway’s recent FDA label expansion for its Deep TMS system. This expansion allows the system to be used as an adjunct therapy for adolescents with major depressive disorder, broadening its market potential. Additionally, the company has shown a strong revenue performance with a 29% increase in 3Q25, surpassing expectations.
Furthermore, Brainsway’s strategic approach, including multi-year lease agreements and minority equity investments, provides a solid foundation for future growth. The company’s increased performance obligations and a growing installed base of Deep TMS systems contribute to a positive outlook. Despite a modest bottom-line miss, the overall financial health, including a significant cash reserve, supports the Buy rating.
Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Emergent Biosolutions, and Genmab. According to TipRanks, Selvaraju has an average return of 23.3% and a 51.40% success rate on recommended stocks.
In another report released yesterday, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $19.00 price target.